Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

Siglecs as Immune Cell Checkpoints in Disease

(2020) Shiteng Duan et al.   Annual Review of Immunology

Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin

(2020) Sophie A. Dusoswa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment

(2020) Stephanie van de Wall et al.   TRENDS IN IMMUNOLOGY

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

(2020) Nicola Mitwasi et al.   Scientific Reports

Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines

(2020) Katharina Zimmermann et al.   Cancers

Targeting glycosylated PD-1 induces potent anti-tumor immunity

(2020) Linlin Sun et al.   CANCER RESEARCH

The Emerging Landscape of Immune Cell Therapies

(2020) Evan W. Weber et al.   CELL

Targeted glycan degradation potentiates the anticancer immune response in vivo

(2020) Melissa A. Gray et al.   Nature Chemical Biology

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

(2019) Jun Wang et al.   NATURE MEDICINE

An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade

(2019) Lynda Vuong et al.   CANCER RESEARCH

Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment

(2019) Quentin Haas et al.   Cancer Immunology Research

Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?

(2019) Stefan Mereiter et al.   CANCER CELL

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

(2019) Heng-Huan Lee et al.   CANCER CELL

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

(2019) Amira A. Barkal et al.   NATURE

L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy

(2019) H. Angharad Watson et al.   Frontiers in Immunology

From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc

(2019) Chirag Dhar et al.   Frontiers in Immunology

Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses

(2019) Heinz Läubli et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The sialoglycan-Siglec glyco-immune checkpoint – a target for improving innate and adaptive anti-cancer immunity

(2019) Anne Bärenwaldt et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Functional diversification of IgGs through Fc glycosylation

(2019) Taia T. Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding

(2019) Nandini Mondal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

(2019) Dhanya K. Nambiar et al.   JOURNAL OF CLINICAL INVESTIGATION

VISTA is an acidic pH-selective ligand for PSGL-1

(2019) Robert J. Johnston et al.   NATURE

A view on drug resistance in cancer

(2019) Neil Vasan et al.   NATURE

Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells

(2019) Sanne Duinkerken et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential

(2019) Silvana T. Tivadar et al.   MOLECULAR CANCER THERAPEUTICS

A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer

(2019) Yao-Tsung Tsai et al.   Molecular Therapy-Nucleic Acids

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

(2018) Chia-Wei Li et al.   CANCER CELL

Sialic acid blockade suppresses tumor growth by enhancing T cell-mediated tumor immunity

(2018) Christian Büll et al.   CANCER RESEARCH

Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease

(2018) Jose D. Pagan et al.   CELL

Insect C-type lectins in innate immunity

(2018) Xiaofeng Xia et al.   DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization

(2018) Fei Zhao et al.   IMMUNITY

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells

(2018) Yumei Li et al.   PLoS One

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk

(2018) Carlos A. Orozco et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities

(2018) Emily Rodrigues et al.   Cancers

A Cartography of Siglecs and Sialyltransferases in Gynecologic Malignancies: Is There a Road Towards a Sweet Future?

(2018) Quentin Haas et al.   Frontiers in Oncology

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells

(2018) Michal A. Stanczak et al.   JOURNAL OF CLINICAL INVESTIGATION

Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma

(2018) David A. Eavarone et al.   PLoS One

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs

(2018) Takashi Angata   Frontiers in Immunology

Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells

(2018) John P. Murad et al.   Frontiers in Immunology

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

(2018) Michael M. Boyiadzis et al.   Journal for ImmunoTherapy of Cancer

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity

(2017) Jillian M. Prendergast et al.   mAbs

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma

(2017) Ahmad A. Tarhini et al.   MELANOMA RESEARCH

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

(2017) Donnele Daley et al.   NATURE MEDICINE

Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation

(2017) Maulik Vyas et al.   OncoImmunology

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2

(2017) Sayed Shahabuddin Hoseini et al.   OncoImmunology

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

(2017) Kristen M. Hege et al.   Journal for ImmunoTherapy of Cancer

The Cosmc connection to the Tn antigen in cancer

(2017) Tongzhong Ju et al.   Cancer Biomarkers

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

(2016) W. Fiedler et al.   EUROPEAN JOURNAL OF CANCER

Importance of membrane-proximal N-glycosylation on integrin β1 in its activation and complex formation

(2016) Sicong Hou et al.   FASEB JOURNAL

Biological roles of glycans

(2016) Ajit Varki   GLYCOBIOLOGY

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion

(2016) Roberto Tinoco et al.   IMMUNITY

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

The Role of Sialyl-Tn in Cancer

(2016) Jennifer Munkley   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression

(2016) Lena Seifert et al.   NATURE

The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9

(2016) Richard Beatson et al.   NATURE IMMUNOLOGY

Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy

(2016) Mahima Swamy et al.   NATURE IMMUNOLOGY

Precision glycocalyx editing as a strategy for cancer immunotherapy

(2016) Han Xiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen

(2016) Christine Sedlik et al.   OncoImmunology

Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen

(2016) C. Fu et al.   HLA

Selectins: initiators of leucocyte adhesion and signalling at the vascular wall

(2015) Rodger P. McEver   CARDIOVASCULAR RESEARCH

Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies

(2015) V. Bachanova et al.   CLINICAL CANCER RESEARCH

C-type lectins in immunity: recent developments

(2015) Ivy M Dambuza et al.   CURRENT OPINION IN IMMUNOLOGY

Sialic acids in cancer biology and immunity

(2015) Oliver M T Pearce et al.   GLYCOBIOLOGY

A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma

(2015) Oren Smaletz et al.   GYNECOLOGIC ONCOLOGY

Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients

(2015) Sabine Heublein et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Lectins with Potential for Anti-Cancer Therapy

(2015) Tammy Yau et al.   MOLECULES

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer

(2015) Andréia Vasconcelos-dos-Santos et al.   Frontiers in Oncology

A Cancer Therapeutic Vaccine based on Clustered Tn-Antigen Mimetics Induces Strong Antibody-Mediated Protective Immunity

(2014) Barbara Richichi et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

(2014) M. K. Gleason et al.   BLOOD

Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense

(2014) Kayluz Frias Boligan et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

(2014) S. Alfonso et al.   CLINICAL CANCER RESEARCH

Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance

(2014) Camilla Jandus et al.   JOURNAL OF CLINICAL INVESTIGATION

Knockdown of Mgat5 Inhibits Breast Cancer Cell Growth with Activation of CD4+ T Cells and Macrophages

(2014) D. Li et al.   JOURNAL OF IMMUNOLOGY

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

Characterization of the Antibody Response against NeuGcGM3 Ganglioside Elicited in Non-Small Cell Lung Cancer Patients Immunized with an Anti-Idiotype Antibody

(2014) A. M. Hernandez et al.   JOURNAL OF IMMUNOLOGY

Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia

(2014) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer

(2014) Heinz Läubli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A red meat-derived glycan promotes inflammation and cancer progression

(2014) Annie N. Samraj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses

(2014) Shiho Chiba et al.   eLife

Carbohydrate-Mimetic Peptides for Pan Anti-Tumor Responses

(2014) Thomas Kieber-Emmons et al.   Frontiers in Immunology

Altered Tumor-Cell Glycosylation Promotes Metastasis

(2014) Irina Häuselmann et al.   Frontiers in Oncology

Involvement of a Non-Human Sialic Acid in Human Cancer

(2014) Annie N. Samraj et al.   Frontiers in Oncology

Unraveling galectin-1 as a novel therapeutic target for cancer

(2013) Lucile Astorgues-Xerri et al.   CANCER TREATMENT REVIEWS

Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer

(2013) N. Remmers et al.   CLINICAL CANCER RESEARCH

MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-α secretion

(2013) Sandra J. van Vliet et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

(2013) C Arndt et al.   LEUKEMIA

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion

(2013) Jason E Hudak et al.   Nature Chemical Biology

Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation

(2013) N. Kawasaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody

(2012) Nobuyoshi Hayashi et al.   CANCER SCIENCE

Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity

(2012) Kirstine Lavrsen et al.   GLYCOCONJUGATE JOURNAL

Coordinate regulation of N-glycosylation gene DPAGT1, canonical Wnt signaling and E-cadherin adhesion

(2012) P. K. Sengupta et al.   JOURNAL OF CELL SCIENCE

Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/ -Catenin Signaling in Human Melanoma Cells

(2012) T. Yaguchi et al.   JOURNAL OF IMMUNOLOGY

Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data

(2012) Ana M. Vázquez et al.   Frontiers in Oncology

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Engagement of the Mannose Receptor by Tumoral Mucins Activates an Immune Suppressive Phenotype in Human Tumor-Associated Macrophages

(2011) P. Allavena et al.   Clinical & Developmental Immunology

Dendritic Cell-specific Intercellular Adhesion Molecule 3-grabbing Non-integrin (DC-SIGN) Recognizes a Novel Ligand, Mac-2-binding Protein, Characteristically Expressed on Human Colorectal Carcinomas

(2011) Motohiro Nonaka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer

(2011) D. Miles et al.   ONCOLOGIST

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen

(2010) S Peinert et al.   GENE THERAPY

T Cell Receptor Signaling Co-regulates Multiple Golgi Genes to EnhanceN-Glycan Branching

(2009) Hung-Lin Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Group BStreptococcussuppression of phagocyte functions by protein-mediated engagement of human Siglec-5

(2009) Aaron F. Carlin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE

Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression

(2008) M. Hedlund et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA